Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis

Abstract excerpt

Significance The current application of messenger RNA (mRNA)-based technology has largely been confined to liver diseases because of the lack of a specific and efficient extrahepatic in vivo systemic mRNA delivery system. Here, we have developed a library of N-series lipid nanoparticles (LNPs) that could specifically regulate the protein composition of protein corona on the surface of LNPs, which allows specific...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Histiocytic Disorders and Treatments
• Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
• Share to Tuberous Sclerosis Complex Research